Disease progression in stage A prostate cancer.
To study the disease progression in stage A prostate cancer, 212 patients with stage A from a group of 3370 patients who underwent transurethral resection of the prostate, or subcapsular prostatectomy during the period 1972-1991 were followed. The stage A cases were subdivided into 103 A1 patients and 109 A2 patients and their subsequent course was followed for an average of 41.7 months (6-174 months). Progression to clinical cancer was found in 12 patients, 2 from A1 and 10 from A2 groups. This progression was evident 40.5 months (14-130 months) after prostatectomy. Eight (67%) of these cases responded to endocrine therapy. The rate of expression of ras p21, and the number of argyrophilic nucleolar organizer regions in stage A cancer cells were greater in progressing than in non-progressing cases. These results indicate that stage A cancer with progression arises mainly from the A2 subgroup and exhibits a distinctly proliferative potential even at small foci.
Amakasu
M
M
Department of Urology, School of Medicine, Chiba University, Japan.
Akimoto
S
S
Akakura
K
K
Masai
M
M
Shimazaki
J
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018450:Disease Progression; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009697:Nucleolus Organizer Region / Q000648:ultrastructure; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000628:therapy; D016283:Proto-Oncogene Proteins p21(ras) / Q000378:metabolism; D012834:Silver; D013194:Staining and Labeling
D012834:Silver; C501009:HRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)